Future Prospects of Global Laboratory Proficiency Testing Market

Image
Laboratory Proficiency Testing Market  The global Laboratory Proficiency Testing Market is estimated to be valued at US$ 1.29 billion in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 - 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Laboratory proficiency testing involves evaluating the performance of laboratories for a given scope of testing through inter-laboratory comparisons. It helps assess the quality and competence of laboratories by determining reproducibility and accuracy of test results. Proficiency testing products are used by laboratories to determine method validity and accuracy, and improve testing processes. Market Key Trends: One of the major trends in the laboratory proficiency testing market is the growing number of accredited medical laboratories. Accreditation assures compliance with ISO 15189 and ISO/IEC 17025 standards, which require participation in proficiency testing programs. Accordi

Dengue Vaccines Market: Drivers, Restraints and Opportunities

Dengue fever, often known as breakbone fever, is a viral virus transmitted by mosquitos that causes a severe flu-like disease. Severe dengue fever is a potentially fatal consequence of the disease. Dengue vaccine is a human vaccine that prevents dengue disease. Dengue vaccine is only indicated for people who have experienced dengue fever before. It is administered in three injections over the course of a year.

 

Global Dengue Vaccine Market: Drivers

Over the forecast period, the worldwide dengue vaccine market is expected to rise due to rising dengue prevalence. According to the Pan American Health Organization, a total of 1,191,815 dengue cases were recorded in the Americas region, with 546,589 being laboratory-confirmed and 5,599 being classed as severe dengue.

Dengue Vaccines Market
Dengue Vaccines Market


 

Furthermore, market expansion is likely to be aided by R&D of live attenuated vaccines. Dengvaxia, for example, was licenced by the US Food and Drug Administration in May 2019 for the prevention of dengue fever caused by all dengue virus serotypes. It's a chimaera vaccine developed with recombinant DNA that's live attenuated and tetravalent.

 

Global Dengue Vaccine Market: Restraints

The market's growth is projected to be hampered by the inability to distinguish dengue fever from other febrile disorders. The symptoms of mosquito-borne infections like Zika, chikungunya virus infection, and dengue fever, for example, are extremely similar, making diagnosis challenging. Furthermore, the market's expansion is projected to be hampered by a lack of understanding of the pathophysiology of dengue infection and a lack of appropriate animal models.

 

Global Dengue Vaccine Market: Opportunities

Dengue fever cases are predicted to rise in metropolitan areas, providing lucrative growth prospects for market players. In July 2018, researchers from the Bruno Kessler Foundation's Center for Information Technology reported that the spread of dengue fever in a non-endemic Brazilian metropolis was similar to a large dengue epidemic in Cairns, Australia, where 95 percent of transmission events were localised within the city. Changes in dengue age trends are also predicted to promote market growth. For example, researchers from Taipei Medical University revealed in February 2018 that the rate of dengue infection increased with age, and that females over the age of 40 had a higher infection rate.

Comments

Popular posts from this blog

Global Disposable Face Mask Market Share

Future Prospects of Global Laboratory Proficiency Testing Market

Global Ophthalmoscopes Market Overview and Impact of Coronavirus (Covid-19) Pandemic